Browse > Article
http://dx.doi.org/10.5352/JLS.2014.24.7.769

Anisomycin, an Inhibitor of Protein Synthesis, Overcomes TRAIL Resistance in Human Hepatocarcinoma Cells via Caspases Activation and Bid Downregulation  

Jin, Cheng-Yun (School of Pharmaceutical Science, Zhengzhou University)
Park, Cheol (Department of Molecular Biology, College of Natural Sciences, Dongeui University)
Hong, Su Hyun (Department of Biochemistry, Dongeui University College of Korean Medicine)
Choi, Yung Hyun (Department of Biochemistry, Dongeui University College of Korean Medicine)
Publication Information
Journal of Life Science / v.24, no.7, 2014 , pp. 769-776 More about this Journal
Abstract
Anisomycin, also known as flagecidin, is an antibiotic produced by Streptomyces griseolus that inhibits protein synthesis by binding to the ribosomal 28S subunit. The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a protein that induces apoptotic cell death. TRAIL primarily causes apoptosis in tumor cells by binding to death receptors. Many human cancer cell lines are refractory to TRAIL-induced cell death. In this study, we investigated whether anisomycin could enhance TRAIL-mediated apoptosis in TRAIL-resistant human hepatocarcinoma Hep3B cells. Treatment with anisomycin and TRAIL alone did not reduce cell viability in Hep3B cells. However, in the presence of TRAIL, the anisomycin concentration dependently reduced the cell viability. Our results indicate that anisomycin sensitizes Hep3B cells to TRAIL-mediated apoptosis and that this occurs, at least partly, via caspase activation. Interestingly, Bid knockdown by small interfering RNA significantly reduced the induction of apoptosis in combination with anisomycin and TRAIL, indicating that anisomycin effectively acts to lower the threshold at which TRAIL-mediated truncated Bid triggers the mitochondrial-mediated apoptosis program in Hep3B cells. Therefore, the use of TRAIL in combination with anisomycin might provide an effective therapeutic strategy for the safe treatment of some TRAIL-resistant cancer cells.
Keywords
Anisomycin; apoptosis; Bid; caspase; TRAIL;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z. and Schwall, R. H. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104, 155-162.   DOI   ScienceOn
2 Campos, C. B., Bedard, P. A. and Linden, R. 2003. Selective involvement of the PI3K/PKB/bad pathway in retinal cell death. J Neurobiol 56, 171-177.   DOI   ScienceOn
3 Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A. and Goodwin, R. G. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682.   DOI   ScienceOn
4 Xia, S., Li, Y., Rosen, E. M. and Laterra, J. 2007. Ribotoxic stress sensitizes glioblastoma cells to death receptor induced apoptosis: requirements for c-Jun NH2-terminal kinase and Bim. Mol Cancer Res 5, 783-792.   DOI   ScienceOn
5 Yamanaka, T., Shiraki, K., Sugimoto, K., Ito, T., Fujikawa, K., Ito, M., Takase, K., Moriyama, M., Nakano, T. and Suzuki, A. 2000. Chemotherapeutic agents augment TRAILinduced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32, 482-490.   DOI   ScienceOn
6 Yang, H., Choi, H. J., Park, S. H., Kim, J. S. and Moon, Y. 2009. Macrophage inhibitory cytokine-1 (MIC-1) and subsequent urokinase-type plasminogen activator mediate cell death responses by ribotoxic anisomycin in HCT-116 colon cancer cells. Biochem Pharmacol 78, 1205-1213.   DOI   ScienceOn
7 Sprick, M. R., Weigand, M. A., Rieser, E., Rauch, C. T., Juo, P., Blenis, J., Krammer, P. H. and Walczak, H. 2000. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12, 599-609.   DOI   ScienceOn
8 Stadheim, T. A. and Kucera, G. L. 2002. c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells. Leuk Res 26, 55-65.   DOI   ScienceOn
9 Wajant, H., Gerspach, J. and Pfizenmaier, K. 2005. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev 16, 55-76.   DOI   ScienceOn
10 Li, J. Y., Huang, J. Y., Li, M., Zhang, H., Xing, B., Chen, G., Wei, D., Gu, P. Y. and Hu, W. X. 2012. Anisomycin induces glioma cell death via down-regulation of PP2A catalytic subunit in vitro. Acta Pharmacol Sin 33, 935-940.   DOI
11 Jin, C. Y., Park, C., Kim, G. Y., Lee, S. J., Kim, W. J. and Choi, Y. H. 2009. Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. Chem Biol Interact 180, 143-150.   DOI   ScienceOn
12 Kim, Y. S., Schwabe, R. F., Qian, T., Lemasters, J. J. and Brenner, D. A. 2002. TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology 36, 1498-1508.
13 Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J. and Ashkenazi, A. 2000. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12, 611-620.   DOI   ScienceOn
14 Hemi, R., Paz, K., Wertheim, N., Karasik, A., Zick, Y. and Kanety, H. 2002. Transactivation of ErbB2 and ErbB3 by tumor necrosis factor-alpha and anisomycin leads to impaired insulin signaling through serine/threonine phosphorylation of IRS proteins. J Biol Chem 277, 8961-8969.   DOI   ScienceOn
15 Croons, V., Martinet, W., Herman, A. G., Timmermans, J. P. and De Meyer, G. R. 2009. The protein synthesis inhibitor anisomycin induces macrophage apoptosis in rabbit atherosclerotic plaques through p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 329, 856-864.   DOI   ScienceOn
16 Dampier, K., Hudson, E. A., Howells, L. M., Manson, M. M., Walker, R. A. and Gescher, A. 2001. Differences between human breast cell lines in susceptibility towards growth inhibition by genistein. Br J Cancer 85, 618-624.   DOI   ScienceOn
17 Grollman, A. P. 1967. Inhibitors of protein biosynthesis. II. Mode of action of anisomycin. J Biol Chem 242, 3226-3233.
18 Iordanov, M. S., Pribnow, D., Magun, J. L., Dinh, T. H., Pearson, J. A., Chen, S. L. and Magun, B. E. 1997. Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA. Mol Cell Biol 17, 3373-3381.   DOI
19 Jin, C. Y., Park, C., Hong, S. H., Han, M. H., Jeong, J. W., Xu, H., Liu, H., Kim, G. Y., Kim, W. J., Yoo, Y. H. and Choi, Y. H. 2013. Synergistic induction of TRAIL-mediated apoptosis by anisomycin in human hepatoma cells via the BH3-only protein Bid and c-Jun/AP-1 signaling pathway. Biomed Pharmacother 67, 321-328.   DOI   ScienceOn
20 Zhang, L., Zhu, H., Davis, J. J., Jacob, D., Wu, S., Teraishi, F., Gutierrez, A., Wang, Y. and Fang, B. 2004. Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death. Cancer Biol Ther 3, 296-301.   DOI
21 Shifrin, V. I. and Anderson, P. 1999. Trichothecene mycotoxins trigger a ribotoxic stress response that activates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase and induces apoptosis. J Biol Chem 274, 13985-13992.   DOI   ScienceOn
22 Pei, Z., Chu, L., Zou, W., Zhang, Z., Qiu, S., Qi, R., Gu, J., Qian, C. and Liu, X. 2004. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 39, 1371-1381.   DOI   ScienceOn
23 Sah, N. K., Munshi, A., Kurland, J. F., McDonnell, T. J., Su, B. and Meyn, R. E. 2003. Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J Biol Chem 278, 20593-20602.   DOI   ScienceOn
24 Seo, B. R., Min, K. J., Kim, S., Park, J. W., Park, W. K., Lee, T. J. and Kwon, T. K. 2013. Anisomycin treatment enhances TRAIL-mediated apoptosis in renal carcinoma cells through the down-regulation of Bcl-2, c-FLIP (L) and Mcl-1. Biochimie 95, 858-865.   DOI   ScienceOn
25 Slipicevic, A., Oy, G. F., Rosnes, A. K., Stakkestad, O., Emilsen, E., Engesaeter, B., Maelandsmo, G. M. and Florenes, V. A. 2013. Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis. Cancer Biol Ther 14, 146-154.   DOI
26 Abayasiriwardana, K. S., Barbone, D., Kim, K. U., Vivo, C., Lee, K. K., Dansen, T. B., Hunt, A. E., Evan, G. I. and Broaddus, V. C. 2007. Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. Mol Cancer Ther 6, 2766-2776.   DOI
27 Liu, Y., Ge, J., Li, Q., Gu, L., Guo, X., Ma, Z. G. and Zhu, Y. P. 2013. Anisomycin induces apoptosis of glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells via activation of mitogen-activated protein kinases p38 and JNK. Neoplasma 60, 101-110.
28 Maag, R. S., Mancini, M., Rosen, A. and Machamer, C. E. 2005. Caspase-resistant Golgin-160 disrupts apoptosis induced by secretory pathway stress and ligation of death receptors. Mol Biol Cell 16, 3019-3027.   DOI   ScienceOn
29 Nakshatri, H., Rice, S. E. and Bhat-Nakshatri, P. 2004. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23, 7330-7344.   DOI   ScienceOn
30 Hadji, A., Clybouw, C., Auffredou, M. T., Alexia, C., Poalas, K., Burlion, A., Feraud, O., Leca, G. and Vazquez, A. 2010. Caspase-3 triggers a TPCK-sensitive protease pathway leading to degradation of the BH3-only protein puma. Apoptosis 15, 1529-1539.   DOI